MTOR and cancer: As reported by Khuri colleagues (Li et al., 2014), mTOR inhibition triggers rapid and sustained activation of the PI3K/Akt survival pathway in the human lung and other types of cancer cells; therefore, the combination of mTOR-targeted therapy with drugs that block PI3K/Akt activation might also be reasonable.